Dataset Information

PLCG1 R707Q mutation is counter selected under targeted therapy in a patient with a hepatic angiosarcoma

ABSTRACT: PLCG1 R707Q mutation is counter selected under targeted therapy in a patient with a hepatic angiosarcoma

PROVIDER: EGAS00001001281 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Publications

Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.

Prenen Hans H Smeets Dominiek D Mazzone Massimiliano M Lambrechts Diether D Sagaert Xavier X Sciot Raf R Debiec-Rychter Maria M

Oncotarget 20151101 34

Hepatic angiosarcoma is a rare and aggressive vascular neoplasm. Pathogenic driver mutations are largely unknown. We present the case of a patient with recurrent hepatic angiosarcoma, who initially showed good response to sunitinib, followed by progression. Using comprehensive molecular techniques, we explored the potential mechanisms of resistance. By low-read-depth whole-genome sequencing, the comparison of copy number aberrations (CNAs) of the primary tumor to the skin metastatic lesion that ...[more]

PMID: 26474454

Similar Datasets

Project description:This work is part of the paper: Generation of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model, Rothweiler S et al, Laboratory Investigation, 2014 (accepted) Hepatic Angiosarcoma (AS) is a rare and highly aggressive tumor of endothelial origin with dismal prognosis. Studies of the molecular biology of AS and treatment options are limited since animal models are rare. We have previously shown that inducible knockout of Notch1 in mice leads to spontaneous formation of hepatic AS. The aim of this study was to 1) establish and characterize a cell line derived from this murine AS, 2) to identify molecular pathways involved in the pathogenesis and potential therapeutic targets, and 3) to generate a tumor transplantation model. AS cells retained specific endothelial properties such as tube formation activity, as well as expression of CD31 and von Willebrand Factor. However, electron microscopy analysis revealed signs of dedifferentiation with loss of fenestrae and loss of contact inhibition. Microarray and pathway analysis showed substantial changes in gene expression and revealed activation of the Myc pathway. Exposing the AS cells to sorafenib reduced migration, filopodia dynamics, and cell proliferation but did not induce apoptosis. In addition, sorafenib suppressed ERK phosphorylation and expression of cyclin D2. Injection of AS cells into NOD/SCID mice resulted in formation of undifferentiated tumors confirming the tumorigenic potential of these cells. Conclusion: We established and characterized a murine model of spontaneous AS formation and hepatic AS cell lines as a useful in vitro tool. Our data demonstrate antitumor activity of sorafenib in AS cells with potent inhibition of migration, filopodia formation, and cell proliferation, which support further evaluation of sorafenib as a novel treatment strategy. In addition, AS cell transplantation provides a subcutaneous tumor model useful for in vivo preclinical drug testing. Mouse liver samples (Notch1 knockout and wild type control, 3 animals per group) and angiosarcoma cell lines (3 independently derived lines) were analyzed.

Dataset Information

PLCG1 R707Q mutation is counter selected under targeted therapy in a patient with a hepatic angiosarcoma

Publications

Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets